Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Get Free Report) was the target of a large growth in short interest in October. As of October 15th, there was short interest totaling 12,328 shares, a growth of 223.8% from the September 30th total of 3,807 shares. Based on an average trading volume of 55,739 shares, the short-interest ratio is currently 0.2 days. Approximately 0.2% of the company’s stock are short sold.
Regentis Biomaterials Price Performance
Shares of NYSEAMERICAN RGNT opened at $1.23 on Thursday. The stock’s 50-day simple moving average is $1.81 and its 200-day simple moving average is $2.94. Regentis Biomaterials has a fifty-two week low of $1.23 and a fifty-two week high of $15.50.
Regentis Biomaterials (NYSEAMERICAN:RGNT – Get Free Report) last posted its earnings results on Friday, September 11th. The company reported ($0.22) earnings per share for the quarter.
Institutional Trading of Regentis Biomaterials
An institutional investor recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new position in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials at the end of the most recent quarter.
Regentis Biomaterials Company Profile
Regentis Biomaterials Ltd. is a clinical-stage medical device company focused on developing regenerative solutions for cartilage repair and other orthopedic applications. The company’s work is centered on biomaterials designed to support the restoration of damaged or diseased tissue.
Regentis’ lead product is GelrinC, an implantable hydrogel intended to treat focal cartilage defects, particularly in the knee. The product is designed to fill the damaged area and provide a scaffold that may support the body’s natural cartilage-repair processes.
See Also
- Five stocks we like better than Regentis Biomaterials
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.
